An independent peptide reference — no sellers, every claim sourced

PNC-27

Also known as p53-derived anticancer peptide PNC-27, PNC27

Synthetic p53-HDM-2 fusion peptide that lyses cancer-cell membranes in the lab; no human trials, sold to patients.

preclinical Immune & longevity research chemical

At a glance

Category
Immune & longevity
Status
research chemical
Route
intraperitoneal, intravenous and intratumoral injection in the animal studies; injected in unvalidated grey-market use
Half-life
No published pharmacokinetics in any species
Sequence
A fusion of two parts: residues 12 to 26 of the p53 protein - the region that binds HDM-2 (MDM2) - joined to a membrane-penetrating and membrane-residency sequence. The p53 portion is what gives the peptide its HDM-2-binding activity. The full construct is given in the primary literature and is not reproduced here.

PNC-27 is an experimental synthetic peptide. It has been studied only in cell culture and in mouse tumour models; a search of the ClinicalTrials.gov registry in July 2026 returns no registered study of it 4, and no published report describes it being given to a human being. It is nevertheless sold online as an 'anticancer peptide', marketed to cancer patients. The distance between the laboratory work and this marketing is total: there is no human efficacy, safety or pharmacokinetic data of any kind, and no established dose.

Doping status: Not listed by name; as a non-approved substance it falls under WADA S0 and is prohibited at all times

Checked against the WADA 2026 Prohibited List. For a specific product and country, Global DRO is the lookup athletes are expected to use — the List names substances, not brand names.

This is a short entry. There is little or no published research on this compound, so there is correspondingly little to report. Empty dosing or reconstitution sections mean no credible figures exist — not that they were left out.

Mechanism of action

PNC-27 fuses the HDM-2-binding region of the tumour-suppressor p53 (residues 12 to 26) to a membrane-penetrating peptide. Its premise is not to restore normal p53 signalling but to exploit a reported observation: HDM-2 (MDM2), the protein that normally keeps p53 in check, is present in the plasma membrane of many cancer cells but not of normal cells. PNC-27 is proposed to bind that membrane HDM-2 and form lytic pores, killing the cell by membranolysis - a necrotic rupture rather than programmed cell death 12. The claimed selectivity rests entirely on cancer-cell membranes carrying HDM-2 while normal-cell membranes do not, a distinction the authors reported in cell lines and reinforced by making a normal cell line susceptible once it was engineered to display HDM-2 on its surface 1.

The whole selectivity argument depends on that membrane-HDM-2 pattern being real, consistent and cancer-specific across human tumours in a living body - something never tested in a person. A peptide that kills by punching holes in membranes has an obvious hazard if, in vivo, the target is less tumour-specific than it appears in a dish.

What the research shows

A body of cell-culture and mouse work, largely from one research group, and nothing in humans. There is no human efficacy, safety or pharmacokinetic data, and no registered clinical trial 4. On the evidence available, anyone injecting PNC-27 is not taking a drug with thin support; they are taking one with no human support at all.

Research in humans

No published human studies of any kind. No trial, no case series, no registry entry, no pharmacokinetics, no tolerability data, no maximum tolerated dose. Nothing has been reported about what PNC-27 does in a human body 4.

Animal and lab research

Sarafraz-Yazdi and colleagues (2010) reported that PNC-27 binds cell-membrane HDM-2 and induces membranolysis selectively in cancer cell lines but not in several untransformed lines, and that transfecting a normal line to express surface HDM-2 made it susceptible 1. Related work found that the intact peptide is required for tumour-cell lysis 2 and that the effect extends to a poorly differentiated human leukaemia line that expresses HDM-2 in its plasma membrane 3. Mouse tumour and xenograft models have been used alongside the cell work. All of it is cell culture and rodent.

Caveats. The evidence comes essentially from one group, and the central claim - a cancer-specific membrane distribution of HDM-2 - has not been independently established in humans. Xenograft and cell-line results are weak predictors of human efficacy or safety, and the whole-body toxicity of a membrane-lytic peptide is unstudied. Grey-market product is additionally of unverified identity and purity. Well over a decade after the principal paper, no clinical trial of PNC-27 has been registered 4.

What it is used for

  • Preclinical research tool for testing the membrane-HDM-2 and membranolysis hypothesis in cancer cells 1
  • Sold online and self-administered by cancer patients as an 'anticancer peptide', with no validated indication, no established dose and no human safety data

Dosing

  • There is no human dose. No trial, no pharmacokinetics, no maximum tolerated dose and no clinical protocol to take a starting dose from: ClinicalTrials.gov lists no study of PNC-27 4.
  • The animal studies used intraperitoneal, intravenous and intratumoral injection in mice 12; converting those to a human dose without any pharmacokinetic or safety data is guesswork, and any figure presented in milligrams for a person is invented.
  • A peptide that works by lysing membranes, given at an unknown dose to a person whose tumour may or may not display the membrane target, is a risk that cannot be estimated from the available data.
  • No circulating protocol is set out below, because no coherent human practice exists to describe - only vendor pages and anecdote. The most concrete harm here is a treatable cancer left untreated while an unproven injectable is used in its place.

These figures describe what the literature and published protocols report. They are not advice and not a dosing instruction.

Reconstitution

No reconstitution or dosing guidance is given here, because providing it would imply that a defensible human dose exists. None does.

Safety

Side effects

  • Unknown in humans - no person has been monitored on PNC-27 in any published study
  • The mechanism is membrane lysis; if the membrane target is not as cancer-specific in a human body as in cell culture, damage to normal cells is the predictable hazard 1
  • Immunogenicity, infusion reactions and off-target membrane toxicity are all unassessed
  • The absence of reported side effects reflects the absence of humans in the literature, not safety

Do not use if

  • Everyone, in the practical sense: there is no indication for which a risk-benefit ratio has been established in a human being
  • Cancer patients relying on it in place of evidence-based treatment - the clearest and most concrete harm is a treatable cancer left untreated while an unproven injectable is used
  • Pregnancy, breastfeeding, children and adolescents - no data, and a mechanism that kills cells by rupturing membranes is a poor candidate for use during development
  • Any use at all outside a controlled preclinical laboratory, given the complete absence of human data

Interactions

Not studied in humans, and not meaningfully in animals. No interaction data of any kind exist, so nothing can be said about how it would combine with chemotherapy, radiotherapy or any other treatment.

Sources